Baird Medical Accelerates U.S. Expansion in Interventional Thyroidology
MWN-AI** Summary
Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) has announced significant strides in its U.S. expansion of interventional thyroidology, particularly focusing on its minimally invasive Microwave Ablation (MWA) technology. This development comes as the company aims to enhance global growth and increase access to advanced treatment options for patients with thyroid conditions.
The initiative is underscored by the recent work of notable medical professionals who have successfully integrated Baird Medical's technologies into their practices. Dr. Samer Nakhle of Palm Medical Group in Las Vegas has utilized these innovative treatments in benign thyroid applications, facilitating wider adoption in various medical settings. Meanwhile, Dr. Sophie Dream, an Associate Professor at the University of Alabama at Birmingham, has harnessed Baird's platforms to effectively manage benign thyroid conditions, further contributing to the national momentum of these technologies.
Mark Saxton, the U.S. CEO of Baird Medical, highlighted the importance of embedding their systems in leading healthcare institutions, stating that recent achievements affirm the company’s commercial strategy and empower physicians with the necessary tools to improve patient care.
Baird Medical specializes in minimally invasive diagnostics and treatments, striving to enhance patient outcomes through precision technology. The company has been making its mark globally, not only holding a leading position in the Chinese market for thyroid microwave ablation but also expanding its product reach to over 20 countries worldwide. Their solutions have been implemented in more than 30 prestigious healthcare facilities across the United States, including major institutions like the Mayo Clinic and UCSF Medical Center.
Baird Medical is positioned at the forefront of medical innovation, with ambitious plans for further expansion and collaboration with leading academic partners.
MWN-AI** Analysis
Baird Medical’s recent announcement of accelerated U.S. expansion in interventional thyroidology positions the company as a key participant in the rapidly growing sector of minimally invasive medical treatments. The utilization of Microwave Ablation (MWA) technology for benign thyroid applications is indicative of Baird's strong market presence, particularly in the western United States, where it has successfully partnered with influential medical professionals.
From an investment perspective, this momentum highlights Baird Medical's strategic focus on expanding access to advanced therapies, which could lead to increased revenue potential. The company's partnerships with academic institutions and leading hospitals—such as the Mayo Clinic and UCSF Medical Center—further validate its technological capabilities and enhance its credibility in the medical community. Such collaborations could serve as a foundation for sustained growth, especially as the market for minimally invasive surgeries continues to expand.
However, potential investors should be aware of the inherent risks associated with Baird Medical's aggressive expansion strategy. As stated in their forward-looking statements, there are uncertainties regarding regulatory conditions, economic factors, and competitive dynamics that could impact performance. The company's reliance on continued innovation and regulatory compliance necessitates careful scrutiny.
In summary, Baird Medical presents a compelling opportunity for investment, given its strong market leadership and innovative approach to medical technology. However, it is crucial for investors to manage expectations and remain cognizant of the risks outlined in their communications. A diversified investment strategy might be prudent, allowing exposure to Baird while mitigating the inherent uncertainties in the healthcare market. Ultimately, monitoring ongoing developments in the company's expansion efforts and industry trends will be key to making informed investment decisions.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
NEW YORK, Feb. 25, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced new clinical progress across the United States. This momentum directly supports the Company's strategy to accelerate global growth and expand patient access to advanced, minimally invasive therapies.
Reinforcing the Company's market leadership in the western United States, Samer Nakhle, M.D., FACE, ECNU, Medical Director of Palm Medical Group in Las Vegas, Nevada, recently leveraged Baird Medical's technology for benign thyroid applications. His work secures broader adoption of these innovative treatments across diverse practice environments.
Sophie Dream, M.D., MPH, FACS, Associate Professor and Chief of the Section of Endocrine Surgery at the University of Alabama at Birmingham, drives this national momentum forward. She utilized Baird Medical's platforms to address benign thyroid conditions, empowering the broader medical community to adopt highly effective, tissue-sparing interventions.
"Integrating our systems into leading academic and private practices drives our core mission," stated Mark Saxton, US CEO of Baird Medical. "These recent milestones validate our commercial roadmap and ensure more physicians have the tools necessary to elevate patient care."
About Baird Medical
Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.
Forward-Looking Statements
This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.
Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.
The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com
SOURCE BDMD
FAQ**
How does Baird Medical Investment Holdings Ltd (BDMD) plan to leverage its recent clinical progress to further penetrate the U.S. market for minimally invasive Microwave Ablation technology?
What specific strategies is Baird Medical Investment Holdings Ltd (BDMD) employing to ensure broader adoption of its advanced treatments across diverse practice environments in the U.S.?
Can you elaborate on how Baird Medical Investment Holdings Ltd (BDMD) intends to foster strategic collaborations with leading academic institutions to enhance patient outcomes in thyroidology?
What risks does Baird Medical Investment Holdings Ltd (BDMD) foresee in its efforts to expand its business in the U.S. and globally, particularly in the context of regulatory challenges and market competition?
**MWN-AI FAQ is based on asking OpenAI questions about Baird Medical Investment Holdings Ltd (NASDAQ: BDMD).
NASDAQ: BDMD
BDMD Trading
-10.73% G/L:
$2.339 Last:
996,077 Volume:
$2.58 Open:
